Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADI 100

Next Previous
X
Search
Drug Profile

ADI 100

Alternative Names: ADI™-100

Latest Information Update: 14 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADiTxT Therapeutics
  • Developer Adimune; ADiTxT Therapeutics
  • Class Antihyperglycaemics; Antipsoriatics; DNA
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Psoriasis; Type 1 diabetes mellitus

Most Recent Events

  • 12 Dec 2024 Adimune plans to submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application for first-in-human clinical trials for ADI 100 in Type 1 Diabetes (T1D), Psoriasis and Stiff-Person Syndrome (SPS)
  • 12 Dec 2024 Pharmacodynamics and adverse events data from the preclinical studies in type 1 diabetes released by Adimune
  • 30 May 2024 ADiTxT Therapeutics plans a clinical trial for Stiff person syndrome in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top